- Home
- OCFT vs CAPR Comparison
OCFT vs CAPR Comparison
Compare OCFT & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCFT
- CAPR
- Stock Information
- Founded
- OCFT 2015
- CAPR 2005
- Country
- OCFT China
- CAPR United States
- Employees
- OCFT N/A
- CAPR N/A
- Industry
- OCFT Computer Software: Programming Data Processing
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OCFT Technology
- CAPR Health Care
- Exchange
- OCFT Nasdaq
- CAPR Nasdaq
- Market Cap
- OCFT 294.4M
- CAPR 324.6M
- IPO Year
- OCFT 2019
- CAPR N/A
- Fundamental
- Price
- OCFT $7.63
- CAPR $6.43
- Analyst Decision
- OCFT Hold
- CAPR Strong Buy
- Analyst Count
- OCFT 1
- CAPR 7
- Target Price
- OCFT $7.98
- CAPR $24.71
- AVG Volume (30 Days)
- OCFT 16.9K
- CAPR 1.4M
- Earning Date
- OCFT 11-13-2025
- CAPR 11-12-2025
- Dividend Yield
- OCFT N/A
- CAPR N/A
- EPS Growth
- OCFT N/A
- CAPR N/A
- EPS
- OCFT N/A
- CAPR N/A
- Revenue
- OCFT $228,020,185.00
- CAPR $13,392,150.00
- Revenue This Year
- OCFT N/A
- CAPR N/A
- Revenue Next Year
- OCFT $6.37
- CAPR $7,894.07
- P/E Ratio
- OCFT N/A
- CAPR N/A
- Revenue Growth
- OCFT N/A
- CAPR N/A
- 52 Week Low
- OCFT $2.08
- CAPR $5.68
- 52 Week High
- OCFT $7.75
- CAPR $22.90
- Technical
- Relative Strength Index (RSI)
- OCFT 66.09
- CAPR 43.50
- Support Level
- OCFT $7.44
- CAPR $6.02
- Resistance Level
- OCFT $7.68
- CAPR $6.56
- Average True Range (ATR)
- OCFT 0.10
- CAPR 0.43
- MACD
- OCFT 0.00
- CAPR -0.11
- Stochastic Oscillator
- OCFT 79.17
- CAPR 19.90
About OCFT OneConnect Financial Technology Co. Ltd.
OneConnect Financial Technology Co Ltd is a technology-as-a-service provider for the financial services industry. It integrates extensive expertise in the industry with market technology to provide technology applications and technology-enabled business services to financial institutions. The integrated solutions and platforms it provides include digital banking solutions, digital insurance solutions, and the Gamma Platform, a technology infrastructure platform for financial institutions. Geographically, the company generates substantially all of its revenue from its business in the People's Republic of China (PRC).
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.